Skip to content

Cost-effectiveness analysis of neoadjuvant chemotherapy versus adjuvant chemotherapy with advanced non-small cell lung cancer during intial treatment phase in real-word setting

Cost-effectiveness analysis of neoadjuvant chemotherapy versus adjuvant chemotherapy with advanced non-small cell lung cancer during intial treatment phase in real-word setting

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097471
Enrollment
Unknown
Registered
2025-02-19
Start date
2024-03-01
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Sponsors

Army Medical Center of PLA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Non-small cell lung cancer patients with TNM stage cT2-4N0-2M0. 2)Patients with clinical diagnosis (ICD-9, ICD-10) of non-small cell lung cancer with clinical stage ?B-?C.

Exclusion criteria

Exclusion criteria: 1) The chemotherapy regimen was non-mainstream and non-traditional. 2) Targeted therapy, radiotherapy, immunotherapy and other treatments other than surgery and chemotherapy were performed in the initial treatment. 3) Patients with clinical stage IIII. 4) The interval between surgery and chemotherapy was greater than 3 months. 5) Delay of chemotherapy for more than 3 months. 6) Coexisting with other tumors. 7) Complicated with other major diseases. 8) R0 resection was not achieved.

Design outcomes

Primary

MeasureTime frame
Overall survival;Progress-Free Survival;Cost;Health utility value;

Secondary

MeasureTime frame
Adverse Events rate of chemotherapy;Surgical complication rate;Completion rate of chemotherapy;Operative mortality;Completion rate of full dose and full course chemotherapy;

Countries

China

Contacts

Public ContactDongdong Wu

Army Medical Center of PLA

604269346@qq.com+86 183 0230 2369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026